Form 8-K AbbVie Inc. For: Jul 03

Go back to Form 8-K AbbVie Inc. For: Jul 03

AbbVie (ABBV) Issues Q2 and FY25 Guidance

July 3, 2025 1:11 PM EDT

AbbVie (NYSE: ABBV):


Reported GAAP earnings and adjusted non-GAAP earnings for the second quarter of 2025 are expected to include acquired IPR&D and milestones expense of $823 million on a pre-tax basis, representing an unfavorable impact of $0.42 to both GAAP diluted earnings per share and... More